Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews · Lung Cancer

No studies found 1 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 0 · 0%High 1 · 33.3%

Progression‐free survival · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) may leads to lower progression‐free survival (PFS) compared with chemotherapy (low certainty).

1 finding from 1 review

Progression‐free survival · People with advanced non‐small cell lung cancer

The review found no eligible studies for this question.

1 finding from 1 review

Progression‐free survival · EGFR M+ patients with NSCLC

Afatinib leads to lower progression‐free survival compared with chemotherapy (high certainty).

1 finding from 1 review